Compare iShares MSCI Taiwan ETF (EWT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Pfizer Inc — how do they compare? iShares MSCI Taiwan ETF trades at $100.15, while Pfizer Inc trades at $25.14 (market cap $141.46B). The key difference: Pfizer Inc pays a 6.93% dividend while iShares MSCI Taiwan ETF pays none, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| EWT | PFE | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $28.56 |
52-Week Low | $58.05 | $23.29 |
Market Cap | — | $141.46B |
Volume | — | 29,869,932 |
Enterprise Value | — | $192.12B |
Dividend Yield | — | 6.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $100.60, down 1.26% on the day amid neutral technical signals. The ETF has delivered exceptional performance with a 100%+ gain in 2026, driven by Taiwan's dominant semiconductor sector and AI infrastructure exposure. Current technical indicators show mixed signals with bullish moving averages but neutral oscillators, while support levels cluster around $99-$101.
The outlook remains favorable given Taiwan's critical role in global semiconductor supply chains and AI infrastructure growth, though stretched valuations and geopolitical tensions with China present significant risks. Institutional interest remains strong due to concentrated exposure to TSMC and other tech leaders, but investors should monitor dollar movements and regional stability.
Pfizer (PFE) trades at $24.25, down 0.94% on the day, with a bearish technical signal from moving averages. The company reported $62.58B in 2025 revenue and a net income margin of 11.83%, with recent quarterly earnings consistently beating expectations. A dividend of $0.43 per share is scheduled for payment on September 1, 2026. The stock's valuation includes a P/E of 18.51 and P/S of 2.19, while analyst consensus price target is $28.25.
Pfizer presents a mixed outlook with stable profitability and a strong dividend, but faces headwinds from patent expirations and competitive pressures. The stock offers value at current levels relative to analyst targets, though technical weakness and revenue declines from peak COVID-era sales pose near-term risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
